UK Health watchdog NICE has recommended Novo Nordisk‘s diabetes drug Victoza for limited use on Britain’s state-run health service the NHS.
NICE has agreed that a 1.2mg once-daily injection of the drug was a clinically and cost-effective option, when used with two oral anti-diabetic tablets for obese patients with type 2 diabetes.
NICE has also requested further information to support the wider use of Victoza in combination with only one anti-diabetic tablet. The draft guidance does not recommend use of the higher 1.8mg dose.
Novo said it was encouraged by the preliminary NICE view and looked forward to further discussions ahead of final guidance being issued around June.
Victoza, also known as liraglutide, belongs to a new class of so-called GLP-1 diabetes drugs that lower glucose levels by stimulating the release of insulin only when glucose levels become too high.